WCG Wealth Advisors LLC Has $1.66 Million Holdings in Sanofi (NASDAQ:SNY)

WCG Wealth Advisors LLC grew its holdings in shares of Sanofi (NASDAQ:SNY) by 12.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,245 shares of the company’s stock after acquiring an additional 3,790 shares during the quarter. WCG Wealth Advisors LLC’s holdings in Sanofi were worth $1,662,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Altrius Capital Management Inc increased its holdings in shares of Sanofi by 1.1% during the second quarter. Altrius Capital Management Inc now owns 160,733 shares of the company’s stock worth $7,799,000 after buying an additional 1,685 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in Sanofi by 9.4% in the 2nd quarter. First Eagle Investment Management LLC now owns 308,282 shares of the company’s stock worth $14,958,000 after purchasing an additional 26,375 shares in the last quarter. Hsbc Holdings PLC raised its position in Sanofi by 2,735.8% in the second quarter. Hsbc Holdings PLC now owns 279,981 shares of the company’s stock valued at $13,661,000 after purchasing an additional 270,108 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Sanofi by 21.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 63,593 shares of the company’s stock valued at $3,044,000 after purchasing an additional 11,404 shares in the last quarter. Finally, Argent Trust Co grew its holdings in shares of Sanofi by 11.7% during the second quarter. Argent Trust Co now owns 23,594 shares of the company’s stock worth $1,145,000 after purchasing an additional 2,478 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ:SNY opened at $58.26 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The company has a 50 day simple moving average of $54.08 and a two-hundred day simple moving average of $50.35. The company has a market capitalization of $147.56 billion, a PE ratio of 29.28, a P/E/G ratio of 1.62 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. During the same period in the prior year, the firm posted $0.95 EPS. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Research analysts anticipate that Sanofi will post 4.25 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SNY shares. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 11th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday. Finally, Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.